OpenNashEarnings

Stryker (SYK) · Medical Devices

Stryker Q2 2026 earnings: summary, key numbers & outlook

Results filed 30 Jul 2026 · Quarter ended 30 Jun 2026

Press release ↗Investor relations ↗

Summaries and transcripts are machine-generated and can contain errors.

In brief

Stryker is recovering from a cyber incident that disrupted supply and left backorders, while Mako installations hit a record Q2 and Triathlon Gold moves toward full commercial launch.

Stryker's quarter was shaped by its recovery from the cybersecurity incident first reported on March 11, 2026. Production ramped back up, but the supply disruption left a meaningful backorder situation and lost sales. Even so, sales grew on higher unit volume across MedSurg and Neurotechnology and Orthopaedics, and Stryker delivered its best ever Q2 for Mako installations.

Management says it enters the second half with regained momentum and wants to keep growing at the high end of MedTech. The plan leans on a steady cadence of innovation, including the move to full commercial launches of Triathlon Gold. The main tension is supply: demand is described as strong, so clearing backorders and avoiding further disruption matters most.

No call transcript for this quarter, so this summary also draws on: Webull (Motley Fool transcript) ↗.

Key numbers

Net sales · GAAP
$6.6B

up 9.4% from a year ago

Net earnings · GAAP
$1.3B

up 44.3% from a year ago

Reported diluted EPS · GAAP
$3.30

up 44.1% from a year ago

Adjusted diluted EPS · non-GAAP
$3.69

up 17.9% from a year ago

Gross profit margin · GAAP
68.3%

Operating income · GAAP
$1.7B

up 49.1% from a year ago

Operating income margin · GAAP
25.2%

Adjusted operating income margin · non-GAAP
27.4%

up 170 bps from a year ago

Segment or metricValueChange
MedSurg and Neurotechnology$3.6Bup 9.7% as reported
Orthopaedics$3.0Bup 9.1% as reported
Medical$1.1Bup 13.4% as reported
Endoscopy$1.0Bup 11.7% as reported
Instruments$1.0Bup 9.3% as reported
Vascular$496.0Mdown 0.7% as reported
Trauma and Extremities$1.1Bup 11.9% as reported
Knees$693.0Mup 8.4% as reported
Where each number comes from
  • Net sales: “Net sales | $6,589 | $6,022 | 9.4% | $12,609 | $11,888 | 6.1% Cost of sales | 2,091 | 2,181”
  • Net earnings: “Net earnings | $1,276 | $884 | 44.3% | $2,021 | $1,538 | 31.4% Net earnings per share of common stock: Basic”
  • Reported diluted EPS: “Reported EPS increased 44.1% to $3.30 •Adjusted EPS(1) increased 17.9% to $3.69”
  • Adjusted diluted EPS: “Reported EPS increased 44.1% to $3.30 •Adjusted EPS(1) increased 17.9% to $3.69”
  • Gross profit margin: “Reported gross profit margin and reported operating income margin were 68.3% and 25.2% in the quarter.”
  • Operating income: “Operating income | $1,659 | $1,113 | 49.1% | $2,595 | $1,950 | 33.1% % of sales | 25.2% | 18.5%”
  • Operating income margin: “Reported gross profit margin and reported operating income margin were 68.3% and 25.2% in the quarter.”
  • Adjusted operating income margin: “Adjusted operating income margin(1) increased 170 bps to 27.4% •Reported EPS increased 44.1% to $3.30”
  • MedSurg and Neurotechnology: “MedSurg and Neurotechnology United States | $2,854 | $2,626 | 8.7% | 8.7% | $5,348 | $5,043 | 6.1% | 6.1% International | 771 | 679 | 13.3 | 11.1 | 1,484 | 1,318 | 12.5 | 8.1 Total | $3,625 | $3,305 | 9.7%”
  • Orthopaedics: “Total | $2,964 | $2,717 | 9.1% | 8.7% | $5,777 | $5,527 | 4.5% | 3.3% Geographic: United States | $4,959 | $4,554”
  • Medical: “Total | $1,122 | $990 | 13.4% | 13.0% | $2,024 | $1,935 | 4.6% | 3.9% Vascular United States | $250 | $268”
  • Endoscopy: “Total | $1,004 | $899 | 11.7% | 11.3% | $1,872 | $1,766 | 6.0% | 5.3% Medical United States | $945 | $840”
  • Instruments: “Total | $1,003 | $918 | 9.3% | 9.0% | $1,923 | $1,756 | 9.6% | 8.9% Endoscopy United States | $819 | $742”
  • Vascular: “Total | $496 | $498 | (0.7)% | (1.8)% | $1,013 | $904 | 11.9% | 9.9% MedSurg and Neurotechnology United States”
  • Trauma and Extremities: “Total | $1,072 | $957 | 11.9% | 11.5% | $2,107 | $1,902 | 10.7% | 9.4% Ortho Tech United States | $530 | $483”
  • Knees: “Total | $693 | $640 | 8.4% | 8.0% | $1,363 | $1,279 | 6.6% | 5.3% Hips United States | $296 | $283”

Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.

From the filingQ2 2026vs year agovs last quarter
Revenue$6.6B+9.4%+9.5%
Operating income$1.7B+49.1%+77.2%
Net income$1.3B+44.3%+71.3%
Diluted EPS$3.30+44.1%+71.0%
Free cash flow$1.1B+14.1%+155.2%
Gross margin68.3%+4.5 pts+5.0 pts
Operating margin25.2%+6.7 pts+9.7 pts

Calculated by code from XBRL, not by the model.

Outlook

MetricPeriodOutlook
Organic net sales growthfull year 20268.3% to 9.3%
Adjusted net earnings per diluted sharefull year 2026$14.95 to $15.10

Key takeaways

  1. Cyber incident recovery drove supply and sales

    Production ramped as recovery continued, but the supply disruption created a meaningful backorder situation with lost sales in the quarter. Restoring supply is the main near-term operating task.

  2. Mako had its best ever Q2 installations

    Stryker focused more on competitive users than on existing Stryker users in these installations, which suggests the robot is winning share from rivals rather than only expanding inside its base.

  3. Triathlon Gold is moving to full commercial launch

    Management said it is rapidly moving to full commercial launches of Triathlon Gold, extending its knee portfolio, where Knees sales grew 8.4% in the quarter.

  4. Demand is not the constraint, backlog is

    Management said orders are already there and that there have been zero cancellations in its books. Backordered demand remains to be fulfilled as supply recovers.

  5. New competitors are limited to part of the market

    Management said some new competitors tend to be more in just the aspiration portion of the market. Stryker is therefore not seeing broad competitive pressure across its robotic offering.

Charts

Revenue$6.6B+9.4% y/yQ2 2026
Q4 2024: $6.4BQ4 ’24$6.4BQ1 2025: $5.9BQ1 ’25$5.9BQ2 2025: $6.0BQ2 ’25$6.0BQ3 2025: $6.1BQ3 ’25$6.1BQ4 2025: $7.2BQ4 ’25$7.2BQ1 2026: $6.0BQ1 ’26$6.0BQ2 2026: $6.6BQ2 ’26$6.6BQ3 2026: $6.5BQ3 ’26$6.5B
Data
Q4 2024$6.4B
Q1 2025$5.9B
Q2 2025$6.0B
Q3 2025$6.1B
Q4 2025$7.2B
Q1 2026$6.0B
Q2 2026$6.6B
Q3 2026$6.5B
Diluted EPS (GAAP)$3.30+44.1% y/yQ2 2026
Q4 2024: $1.41Q4 ’24$1.41Q1 2025: $1.69Q1 ’25$1.69Q2 2025: $2.29Q2 ’25$2.29Q3 2025: $2.22Q3 ’25$2.22Q4 2025: $2.20Q4 ’25$2.20Q1 2026: $1.93Q1 ’26$1.93Q2 2026: $3.30Q2 ’26$3.30Q3 2026: $1.96Q3 ’26$1.96
Data
Q4 2024$1.41
Q1 2025$1.69
Q2 2025$2.29
Q3 2025$2.22
Q4 2025$2.20
Q1 2026$1.93
Q2 2026$3.30
Q3 2026$1.96

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin25.2%+6.7 pts y/yQ2 2026
Q4 2024: 9.0%Q4 ’249.0%Q1 2025: 14.3%Q1 ’2514.3%Q2 2025: 18.5%Q2 ’2518.5%Q3 2025: 18.7%Q3 ’2518.7%Q4 2025: 25.2%Q4 ’2525.2%Q1 2026: 15.5%Q1 ’2615.5%Q2 2026: 25.2%Q2 ’2625.2%Q3 2026: 15.9%Q3 ’2615.9%
Data
Q4 20249.0%
Q1 202514.3%
Q2 202518.5%
Q3 202518.7%
Q4 202525.2%
Q1 202615.5%
Q2 202625.2%
Q3 202615.9%
Free cash flow$1.1B+14.1% y/yQ2 2026
Q4 2024: $1.7BQ4 ’24$1.7BQ1 2025: $127.0MQ1 ’25$127.0MQ2 2025: $928.0MQ2 ’25$928.0MQ3 2025: $1.4BQ3 ’25$1.4BQ4 2025: $1.9BQ4 ’25$1.9BQ1 2026: $415.0MQ1 ’26$415.0MQ2 2026: $1.1BQ2 ’26$1.1BQ3 2026: $1.2BQ3 ’26$1.2B
Data
Q4 2024$1.7B
Q1 2025$127.0M
Q2 2025$928.0M
Q3 2025$1.4B
Q4 2025$1.9B
Q1 2026$415.0M
Q2 2026$1.1B
Q3 2026$1.2B

Operating cash flow minus capital expenditure, from cash flow statements.

Questions

How did the cyber incident affect Stryker's business this quarter?

Stryker's recovery continued as it ramped overall production, but the supply disruption resulted in a meaningful backorder situation with lost sales. Management said it made significant progress in recovering and enters the second half with regained momentum.

How is Mako performing?

Stryker delivered its best ever Q2 for Mako installations. It focused more on competitive users than existing Stryker users.

Is demand for Stryker's products healthy?

Management said orders are already there, so demand is not the problem, and it has seen zero cancellations in its books. Organic sales growth came from increased unit volume.

What new products is Stryker launching?

Stryker said it is rapidly moving to full commercial launches of Triathlon Gold. The sources give no further detail on launch timing.

Is Stryker facing new competition?

Management said there are some new competitors, which tend to be more in just the aspiration portion of the market. Stryker also faces pricing pressure and changes in the competitive environment as listed risks.

Documents

From Stryker investor relations

SEC filing